By 2025, innovations such as lab-on-a-chip technology, automation, and CRISPR-Cas9 gene editing are expected to enhance ...

In this installment, we delve into one of the most debated scientific advancements of our time: CRISPR gene-editing ...

Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, CRSP is yet to record product sales.

CRISPR is a powerful gene-editing tool that holds enormous potential for treating genetic diseases by allowing scientists to ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...

Researchers have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal neurodegenerative condition. The treatment, which uses ...

The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...